AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30302786 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (0.6-18.0 mg, n=18)
Number of subjects: 25
Study 30302786 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 25
Study 30302786 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (n=8)
Number of subjects: 25
Study 28675594 — intervention group
Group type: COMPARATOR
Intervention: Single-dose letermovir (120, 240, 480, 720, and 960 mg)
Number of subjects: 16
Study 28675594 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose letermovir (240 mg, once-daily)
Number of subjects: 16
Study 28675594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24950277 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous phlebectomy
Number of subjects: 101
Study 24950277 — intervention group
Group type: COMPARATOR
Intervention: Delayed varicosity treatment
Number of subjects: 101
Study 24495792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus rosuvastatin (combination group)
Number of subjects: 159
Study 24495792 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (group)
Number of subjects: 159
Study 24495792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (group)
Number of subjects: 159
Study 24495792 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study 22814578 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (50 mg po three times daily)
Number of subjects: 106
Study 22814578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 20575722 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (store-and-forward)
Number of subjects: 3000
Study 17927554 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-Induction (anger) with experiential suppression
Number of subjects: 187
Study 17927554 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-Induction (anxiety) with expressive suppression
Number of subjects: 187
Study 17927554 — intervention group
Group type: COMPARATOR
Intervention: Emotion-Induction (anger) with nonsuppression
Number of subjects: 187
Study 17927554 — intervention group
Group type: COMPARATOR
Intervention: Emotion-Induction (anxiety) with nonsuppression
Number of subjects: 187
Study 17927554 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-Induction (anger) with expressive suppression
Number of subjects: 187
Study 17927554 — intervention group
Group type: COMPARATOR
Intervention: Emotion-Induction (anxiety) with experiential suppression
Number of subjects: 187
Study 16371925 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (two capsules of Oxy-Q containing 480 mg of curcumin and 20 mg of quercetin)
Number of subjects: 43
Study 16371925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (one capsule of Oxy-Q containing 480 mg of curcumin and 20 mg of quercetin)
Number of subjects: 43
Study 16371925 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 43
Study 16371925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (one capsule of Oxy-Q)
Number of subjects: 43
Study 16371925 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (two capsules of Oxy-Q)
Number of subjects: 43
Study 16371925 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) and Low dose (one capsule of Oxy-Q)
Number of subjects: 43
Study 12669769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of rifampicin, isoniazid, and pyrazinamid (Trifazid)
Number of subjects: 16
Study 12669769 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of rifampicin, isoniazid, and pyrazinamid
Number of subjects: 16
Study 9825266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 0
Study 7917561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus nadolol (mean final dose: 82 +/- 31 mg/d)
Number of subjects: 40
Study 7917561 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 40
Study 7917561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus nadolol
Number of subjects: 40
Study 2560548 — intervention group
Group type: COMPARATOR
Intervention: 0% delta 9‐THC
Number of subjects: 12
Study 2560548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3% delta 9‐THC
Number of subjects: 12
Study 2560548 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7% delta 9‐THC
Number of subjects: 12
Study 380184 — intervention group
Group type: EXPERIMENTAL
Intervention: iopronic acid (4.5 g Oravue, Squibb)
Number of subjects: 98
Study 380184 — intervention group
Group type: COMPARATOR
Intervention: iopanoic acid (3 g Telepaque, Winthrop)
Number of subjects: 98
Study 30782258 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg moclobemide tablets (Jelfa)
Number of subjects: 10
Study 30782258 — intervention group
Group type: COMPARATOR
Intervention: 150 mg Aurorix tablets (Hoffmann la Roche)
Number of subjects: 10
Study 29109107 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site with vaccine information and interactive social media components (VSM)
Number of subjects: 888
Study 29109107 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site with vaccine information (VI)
Number of subjects: 888
Study 29109107 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 888
Study 26196188 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch to paliperidone palmitate
Number of subjects: 154
Study 26196188 — intervention group
Group type: COMPARATOR
Intervention: Delayed switch to paliperidone palmitate
Number of subjects: 154
Study 26196188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 23981400 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure using a TENS acupressure apparatus applied at SP6, ST36, SP10, and LI11 points, three times per week for 6 weeks (total of 18 sessions)
Number of subjects: 78
Study 23981400 — intervention group
Group type: COMPARATOR
Intervention: Control group received no acupressure
Number of subjects: 78
Study 23981400 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 78
Study 21856226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 846
Study 21856226 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 846
Study 21856226 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 846
Study 19426108 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin solution (100 unit/ml) irrigation
Number of subjects: 79
Study 19426108 — intervention group
Group type: COMPARATOR
Intervention: Saline solution irrigation
Number of subjects: 79
Study 19426108 — intervention group
Group type: COMPARATOR
Intervention: Saline solution irrigation with anti-platelet medication
Number of subjects: 79
Study 19426108 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin solution irrigation with anti-platelet medication
Number of subjects: 79
Study 18945220 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute counseling visit with AUDIT screening and health promotion booklet discussion (experimental group)
Number of subjects: 275
Study 18945220 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 275
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncycloplegic retinoscopy (NCR)
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinomax Autorefractor
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: SureSight Vision Screener
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lea Symbols test
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Refractor II
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: HOTV VA test
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Dot E stereoacuity
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereo Smile II
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover-uncover test
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: MTI photoscreener
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: iScreen photoscreener
Number of subjects: 2588
Study 15051194 — intervention group
Group type: EXPERIMENTAL
Intervention: NCR, Retinomax Autorefractor, Lea Symbols VA test
Number of subjects: 2588
Study 12188988 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interview
Number of subjects: 120
Study 12188988 — intervention group
Group type: COMPARATOR
Intervention: Information package
Number of subjects: 120
Study 9719164 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin infusion 100 ml three times per week for 2 weeks
Number of subjects: 22
Study 9719164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no albumin infusion)
Number of subjects: 22
Study 9719164 — intervention group
Group type: EXPERIMENTAL
Intervention: Four weeks after withdrawal of albumin infusion
Number of subjects: 22
Study 7661351 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight
Number of subjects: 950
Study 7661351 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscope
Number of subjects: 950
Study 2673623 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg t.i.d.
Number of subjects: 16
Study 2673623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine 10 mg b.i.d.
Number of subjects: 16
Study 2673623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1273208 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.25 mg
Number of subjects: 5
Study 1273208 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5 mg
Number of subjects: 5
Study 1273208 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 5
Study 11294464 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 706
Study 11294464 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 706
Study 11294464 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and Methohexital
Number of subjects: 706
Study 31354513 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration group (WBVG)
Number of subjects: 38
Study 29020329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (VITD3) 50000 IU monthly plus daily multivitamin containing VITD3 400 IU and calcium 162 mg
Number of subjects: 214
Study 29020329 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus daily multivitamin containing VITD3 400 IU and calcium 162 mg
Number of subjects: 214
Study 26857941 — intervention group
Group type: EXPERIMENTAL
Intervention: Team competition environment (n = 200)
Number of subjects: 422
Study 26857941 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 222)
Number of subjects: 422
Study 23955924 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress and Adversity Inventory (STRAIN) coupled with a related lecture and discussion
Number of subjects: 164
Study 23955924 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress and Adversity Inventory (STRAIN) paired with a general stress lecture
Number of subjects: 164
Study 23955924 — intervention group
Group type: EXPERIMENTAL
Intervention: STRAIN-specific lecture
Number of subjects: 164
Study 23955924 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 164
Study 21290113 — intervention group
Group type: COMPARATOR
Intervention: Irradiated hamstring tendon allograft (Ir‐Allo)
Number of subjects: 78
Study 21290113 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐irradiated hamstring tendon allograft (Non‐ir‐Allo)
Number of subjects: 78
Study 20513595 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of heparin + a glycoprotein IIb/IIIa inhibitor
Number of subjects: 17421
Study 20513595 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin alone
Number of subjects: 17421
Study 20513595 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding (non-CABG-related)
Number of subjects: 17421
Study 20513595 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on 6 baseline measures plus anticoagulation regimen
Number of subjects: 17421
Study 18062901 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan 0.1 microg/kg/min for 24 hours
Number of subjects: 42
Study 18062901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15616225 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (RT&WL group)
Number of subjects: 36
Study 15616225 — intervention group
Group type: COMPARATOR
Intervention: Control program (WL group)
Number of subjects: 36
Study 12045757 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 5 mg
Number of subjects: 65
Study 12045757 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 10 mg
Number of subjects: 65
Study 12045757 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 15 mg
Number of subjects: 65
Study 12045757 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 65
Study 12045757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 9527752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (3 mg)
Number of subjects: 60
Study 9527752 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate-dipotassium (20 mg)
Number of subjects: 60
Study 9527752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7614911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (50 mg/kg)
Number of subjects: 18
Study 7614911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2558705 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon-coated polyglycolic acid (Dexon plus)
Number of subjects: 1574
Study 2558705 — intervention group
Group type: COMPARATOR
Intervention: Chromic catgut
Number of subjects: 1574
Study 2558705 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 1574
Study 2558705 — intervention group
Group type: COMPARATOR
Intervention: Silk
Number of subjects: 1574
Study 2558705 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcuticular sutures
Number of subjects: 1574
Study 2558705 — intervention group
Group type: COMPARATOR
Intervention: Interrupted transcutaneous sutures
Number of subjects: 1574
Study 775990 — intervention group
Group type: EXPERIMENTAL
Intervention: Loridine-Keflex prophylaxis (antibiotics)
Number of subjects: 32
Study 775990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30116989 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program and counseling program
Number of subjects: 120
Study 29275697 — intervention group
Group type: EXPERIMENTAL
Intervention: General functioning improvement treatments
Number of subjects: 118
Study 26842502 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week physical activity intervention including shorter outdoor playtime (4 × 30 min), new portable play equipment, and staff training (1 × 4 hr workshop)
Number of subjects: 22
Study 26842502 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week physical activity intervention
Number of subjects: 22
Study 26842502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22
Study 24549371 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39758979 (H(4)R antagonist)
Number of subjects: 0
Study 23032552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine 200 mg orally 3 times daily for 4 weeks
Number of subjects: 59
Study 23032552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19514441 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and correction of hemostatic disorders during intraoperative and postoperative periods
Number of subjects: 37
Study 17055756 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT+PTA
Number of subjects: 56
Study 17055756 — intervention group
Group type: COMPARATOR
Intervention: OMT
Number of subjects: 56
Study 16336830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA)
Number of subjects: 30
Study 16336830 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) combined with DA
Number of subjects: 30
Study 11673584 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlimomab
Number of subjects: 625
Study 11673584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 9389860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1 ml (10 mg)
Number of subjects: 10
Study 9389860 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl 1 ml (placebo)
Number of subjects: 10
Study 9389860 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (second injection)
Number of subjects: 10
Study 7948796 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (2 mg/kg bolus during CPB)
Number of subjects: 0
Study 3358596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular epinephrine irrigation
Number of subjects: 28
Study 3358596 — intervention group
Group type: COMPARATOR
Intervention: Control group (without intraocular epinephrine irrigation)
Number of subjects: 28
Study 31198594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (600 μg)
Number of subjects: 200
Study 31198594 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 200
Study 28017787 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 80
Study 28017787 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 80
Study 25451336 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) - 2 hospital-based sessions and 1 home-based session per week for 12 weeks after PTA.
Number of subjects: 50
Study 25451336 — intervention group
Group type: COMPARATOR
Intervention: PTA alone (Control group) - no additional follow-up regarding exercise.
Number of subjects: 50
Study 25451336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SET and Control)
Number of subjects: 50
Study 24564041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy plus medications (analgesics, nonsteroidal anti-inflammatory - diclofenac sodium)
Number of subjects: 16
Study 24564041 — intervention group
Group type: COMPARATOR
Intervention: Standard medications (analgesics, nonsteroidal anti-inflammatory - diclofenac sodium)
Number of subjects: 16
Study 22247928 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% lidocaine cream
Number of subjects: 59
Study 22247928 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 59
Study 18936474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib with paclitaxel and carboplatin (VPC)
Number of subjects: 181
Study 18936474 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (PC)
Number of subjects: 181
Study 18936474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib monotherapy
Number of subjects: 181
Study 16476120 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) for 3 months
Number of subjects: 34
Study 16476120 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapies only (Control)
Number of subjects: 34
Study 12897047 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/day of Zn as Zn gluconate)
Number of subjects: 0
Study 12897047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10650326 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 0
Study 10650326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9433655 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily for 10 days with theophylline
Number of subjects: 16
Study 9433655 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 9433655 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily for 14 days with warfarin
Number of subjects: 16
Study 9433655 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 16
Study 8431336 — intervention group
Group type: EXPERIMENTAL
Intervention: Free clear fluids intake until premedication (mean 388 ml in 6 h before surgery)
Number of subjects: 100
Study 8431336 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasted for 6 h)
Number of subjects: 100
Study 3315603 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC) 30 units
Number of subjects: 87
Study 3315603 — intervention group
Group type: COMPARATOR
Intervention: Heparin treatment
Number of subjects: 87
Study 31744865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy
Number of subjects: 2167
Study 29080119 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 35
Study 24619763 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 70 mg/week (n=41)
Number of subjects: 125
Study 24619763 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RAL) 60 mg/d (n=37)
Number of subjects: 125
Study 24619763 — intervention group
Group type: COMPARATOR
Intervention: No additional medication (n=47)
Number of subjects: 125
Study 22450724 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.02 mg/mL)
Number of subjects: 81
Study 22450724 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 1 (0.04 mg/mL)
Number of subjects: 81
Study 22450724 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 2 (0.08 mg/mL)
Number of subjects: 81
Study 22450724 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 81
Study 20707886 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic wheelchair trainer with haptic guidance
Number of subjects: 23
Study 20707886 — intervention group
Group type: COMPARATOR
Intervention: Training without guidance
Number of subjects: 23